SCHEMBL6938997

SCHEMBL6938997

O=C(NCc1cccc2ccccc12)c1cc([N+](=O)[O-])ccc1N[C@H]1CC[C@@H](O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.51
FLT3 P36888 1/20 0.50
TYRO3 Q06418 1/20 0.50
MERTK Q12866 1/20 0.50
GAS6 Q14393 1/20 0.50
KMT2A Q03164 6/20 0.48
MEN1 O00255 4/20 0.48
RORC P51449 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
CYP19A1 P11511 1/20 0.40
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
NPC1 O15118 1/20 0.40
TNF P01375 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6938994 1.00 MAPT (0.51) MAPTFLT3TYRO3MERTKGAS6
SCHEMBL7366155 0.93 MAPT (0.60) MAPTKMT2AMEN1RORCTDP1
SCHEMBL6937256 0.86 MAPT (0.59) MAPTKMT2AMEN1GAANPC1
SCHEMBL6937260 0.86 MAPT (0.59) MAPTKMT2AMEN1GAANPC1
SCHEMBL6940140 0.84 FLT3 (0.53) MAPTFLT3TYRO3MERTKGAS6
SCHEMBL6940136 0.84 FLT3 (0.53) MAPTFLT3TYRO3MERTKGAS6
SCHEMBL6944589 0.83 MAPT (0.55) MAPTFLT3TYRO3MERTKGAS6
SCHEMBL6944586 0.83 MAPT (0.55) MAPTFLT3TYRO3MERTKGAS6
SCHEMBL6941778 0.82 MAPT (0.63) MAPTKMT2AMEN1GAANPC1
SCHEMBL6943781 0.82 MAPT (0.49) MAPTFLT3TYRO3MERTKGAS6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP claimed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US claimed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN claimed
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885FLT3 1209/4885TYRO3 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.